Bicocca Open Archive

Logo unimib boa
GORI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.894
AS - Asia 7.848
EU - Europa 6.642
SA - Sud America 1.270
Continente sconosciuto - Info sul continente non disponibili 960
AF - Africa 198
OC - Oceania 7
Totale 35.819
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.754
SG - Singapore 2.861
CN - Cina 1.572
IT - Italia 1.496
HK - Hong Kong 1.203
RU - Federazione Russa 1.064
BR - Brasile 941
CA - Canada 935
VN - Vietnam 908
SE - Svezia 775
IE - Irlanda 732
DE - Germania 685
UA - Ucraina 456
GB - Regno Unito 353
FR - Francia 285
IN - India 247
BD - Bangladesh 209
FI - Finlandia 205
AT - Austria 160
TR - Turchia 145
AR - Argentina 120
IQ - Iraq 103
ID - Indonesia 100
MX - Messico 87
DK - Danimarca 85
ZA - Sudafrica 69
JP - Giappone 59
SA - Arabia Saudita 59
NL - Olanda 58
PK - Pakistan 52
KR - Corea 49
RO - Romania 48
EC - Ecuador 46
CO - Colombia 43
ES - Italia 43
BE - Belgio 41
PL - Polonia 40
PH - Filippine 38
UZ - Uzbekistan 38
VE - Venezuela 33
CL - Cile 31
CR - Costa Rica 25
MA - Marocco 24
JM - Giamaica 23
TN - Tunisia 20
JO - Giordania 19
MY - Malesia 19
PY - Paraguay 19
CH - Svizzera 18
AE - Emirati Arabi Uniti 17
IR - Iran 16
NP - Nepal 16
CZ - Repubblica Ceca 15
ET - Etiopia 15
IL - Israele 15
KE - Kenya 15
EG - Egitto 14
OM - Oman 14
HN - Honduras 13
PA - Panama 13
PE - Perù 13
TH - Thailandia 12
AZ - Azerbaigian 11
KZ - Kazakistan 11
LB - Libano 11
LT - Lituania 11
UY - Uruguay 11
BO - Bolivia 10
TT - Trinidad e Tobago 10
AL - Albania 9
BH - Bahrain 9
EE - Estonia 9
EU - Europa 9
GR - Grecia 9
DO - Repubblica Dominicana 8
PT - Portogallo 8
BG - Bulgaria 7
AU - Australia 6
SN - Senegal 6
TW - Taiwan 6
DZ - Algeria 5
MD - Moldavia 5
PS - Palestinian Territory 5
SY - Repubblica araba siriana 5
BB - Barbados 4
BY - Bielorussia 4
BZ - Belize 4
HR - Croazia 4
NG - Nigeria 4
SV - El Salvador 4
AO - Angola 3
GT - Guatemala 3
KG - Kirghizistan 3
KH - Cambogia 3
LY - Libia 3
ML - Mali 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BQ - ???statistics.table.value.countryCode.BQ??? 2
BW - Botswana 2
Totale 34.815
Salva come PNG Salva come JPEG
Città #
Singapore 1.615
Ashburn 1.579
Ann Arbor 1.412
Woodbridge 1.346
Fairfield 1.231
Hong Kong 1.186
Houston 1.036
San Jose 988
Chandler 745
Dublin 716
Toronto 657
Jacksonville 576
Wilmington 547
Seattle 486
Milan 478
Cambridge 436
Frankfurt am Main 436
New York 426
Dearborn 319
Princeton 282
Council Bluffs 273
Ho Chi Minh City 273
Chicago 271
Santa Clara 270
Los Angeles 265
Beijing 224
Dallas 224
The Dalles 223
Hanoi 205
Nanjing 151
Altamura 133
Lauterbourg 133
Lawrence 133
Shanghai 126
Rome 125
Moscow 122
Vienna 122
Buffalo 112
Lachine 111
São Paulo 99
Dong Ket 83
Hefei 83
San Diego 77
Boardman 76
Helsinki 76
Ottawa 58
Jakarta 54
Andover 51
Phoenix 51
Fremont 50
London 49
Tokyo 48
Munich 47
Nanchang 47
Galati 43
Seoul 42
Hebei 41
Orem 41
Brussels 40
Denver 40
Shenyang 40
Baghdad 39
Columbus 39
Montreal 39
Atlanta 36
Brooklyn 36
Salt Lake City 36
Nuremberg 35
Rio de Janeiro 35
Johannesburg 32
Guangzhou 31
Tashkent 31
Florence 30
Hangzhou 30
Norwalk 30
Falls Church 27
Da Nang 26
Washington 26
Boston 25
Figino 25
Kent 25
Tianjin 25
Warsaw 25
Miami 24
Amsterdam 23
Changsha 23
Turin 22
Brasília 21
Haiphong 21
Jeddah 21
Pune 21
San Francisco 20
San José 20
Charlotte 19
Riyadh 19
Chennai 18
Cuauhtémoc 18
Edmonton 18
New Delhi 18
Philadelphia 18
Totale 22.256
Salva come PNG Salva come JPEG
Nome #
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells 483
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 429
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 363
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 353
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 342
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 341
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 339
Primary Whipple disease of the Central Nervous System presenting with rhombencephalitis 339
The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection 337
Strategies to limit immune-activation in HIV patients 336
HIV testing: A must for patients with inflammatory bowel disease 335
Brachial and central blood pressure in HIV-infected subjects 335
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 335
Comment on "Management of infections in cirrhotic patients: Report of a consensus conference" S Fagiuoli et al. [Dig Liver Dis 2014;46:204-212] 324
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 324
Combination versus sequential monotherapy in chronic HBV infection: A mathematical approach 322
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 315
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 314
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 312
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 311
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 310
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 306
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 303
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 301
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 301
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 297
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 293
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 293
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 292
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 292
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 281
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 278
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 274
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 273
Arterial structure and function in AIDS patients: the impact of renal damage. 271
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 270
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 266
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 265
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 261
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 260
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 260
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 260
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 260
Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study 259
Unmasking tuberculosis in the era of antiretroviral treatment 259
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 259
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 259
Neurocognitive impairment in HIV infected naïve patients: the role of genetic polymorphisms, viral changes and intrathecal immune activation 257
Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function 257
Focal bone lesions in hiv-positive patient treated with tenofovir 257
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 257
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 255
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 253
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 251
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 250
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 250
The immunomodulatory nutritional intervention NR100157 reduced CD4 + T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study) 248
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 247
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 246
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 243
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 242
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 242
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 242
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 239
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 239
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 237
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 237
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 236
Effects of antiretroviral therapy on endothelial function in HIV patients. 235
Structural and functional alterations of large arteries in HIV patients and their relationships with metabolic syndrome. 235
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 234
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 234
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 232
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 230
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial 228
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 226
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 222
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis 222
Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy 222
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: A multilevel analysis 221
Associations between immune depression and cardiovascular events in HIV infection 221
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 221
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study 220
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 218
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 218
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 218
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy 218
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 217
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 216
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 214
Beyond the gut bacterial microbiota: The gut virome 212
Impact of HAART with protease inhibitors treatment on carotid wall structure in HIV patients. 212
Antimicrobial therapy duration: A major matter in the management of severe infections 211
To the editor 211
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 211
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 211
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 210
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure 210
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: A combined approach by QuantiFERON®-TB Gold and tuberculin skin tests 207
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 207
Totale 26.601
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.597
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.597
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.154 0 0 0 146 73 135 61 124 72 118 116 309
2022/20232.909 369 803 233 291 188 471 31 167 210 28 72 46
2023/20242.086 43 72 97 81 283 552 427 80 145 49 35 222
2024/20254.704 285 525 358 211 390 156 241 170 571 748 366 683
2025/202611.274 1.129 635 815 1.005 1.237 612 1.463 522 929 993 1.004 930
2026/20272.738 338 408 1.182 810 0 0 0 0 0 0 0 0
Totale 35.819